ZLDAF (Zelira Therapeutics) Other Stockholders Equity: $0.00 Mil (As of Jun. 2025)


ZLDAF Zelira Therapeutics Ltd ZLDAF
10 GF Score
Price $0.35
GF Value $0.08
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics Other Stockholders Equity?

Zelira Therapeutics ZLDAF 10 Other Stockholders Equity is $0.00 Mil as of Jun. 2025. GuruFocus rates ZLDAF with a GF Score™ of 10/100 and a GF Value™ of $0.08. The stock has 7 warning signs investors should review.

Zelira Therapeutics's Other Stockholders Equity for the quarter that ended in Jun. 2025 was $0.00 Mil.

Zelira Therapeutics's quarterly Other Stockholders Equity declined from Jun. 2024 ($0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then increased from Dec. 2024 ($-0.00 Mil) to Jun. 2025 ($0.00 Mil).

Zelira Therapeutics's annual Other Stockholders Equity increased from Jun. 2023 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) and increased from Jun. 2024 ($0.00 Mil) to Jun. 2025 ($0.00 Mil).

Zelira Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Other Stockholders Equity Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
ZLDAF
10GF Score
Zelira Therapeutics Ltd ZLDAF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelira Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Zelira Therapeutics (ZLDAF) has a Other Stockholders Equity of $0.00 Mil as of Jun. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Other Stockholders Equity too high?
Zelira Therapeutics' current Other Stockholders Equity is $0.00 Mil. Overall, Zelira Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' Other Stockholders Equity compare to MTNB and SXTP?
Zelira Therapeutics' Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ZLDAF) has a current Other Stockholders Equity of $0.00 Mil. The stock's GF Value™ is $0.08, compared to a current price of $0.35 — trading 337.5% above its estimated fair value. The current Other Stockholders Equity is $0.00 Mil. Zelira Therapeutics' overall GF Score™ is 10/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current Other Stockholders Equity is $0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of $0.35 is trading 337.5% above its estimated GF Value™ of $0.08.

Key valuation signals for ZLDAF:

  • Other Stockholders Equity: $0.00 Mil
  • GF Value™: $0.08 vs. price of $0.35 (337.5% above fair value)
  • GF Score™: 10/100 with 7 warning signs

No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
10GF Score

Get the complete analysis for ZLDAF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price
$0.08
GF Value